---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-21-000183"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T01:16:05.059611+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CryoLife sells PerClot to Baxter for up to $60.8M; Q2 revenue up 42% to $76.1M

## Summary
- Total consideration up to $60.8M: $25M at closing ($19M to CryoLife), $25M upon FDA PMA approval, $10M sales milestones.
- CryoLife retains FDA costs through Dec 31, 2022; Baxter may assume after Jan 1, 2023.
- Q2 2021 revenue $76.1M, up 42% GAAP vs Q2 2020 $53.8M; net loss ($2.2M) ($0.06/shr); non-GAAP net income $4.8M ($0.12/shr).
- FY2021 revenue guidance $296-300M; Q3 2021 expected $71-73M, with PerClot minimal in H2 due to sale.

## SEC filing metadata
- accession: 0000784199-21-000183
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419921000183/0000784199-21-000183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419921000183/cry-20210729x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-21-000183
- JSON: https://secwatch.observer/filing/0000784199-21-000183.json
- Plain text: https://secwatch.observer/filing/0000784199-21-000183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.